Axoltis Pharma - About the company
Axoltis Pharma is a series A company based in Clermont Ferrand (France), founded in 2003. It operates as a Diversified pharmaceutical company. Axoltis Pharma has raised $20.9M in funding.
Company Details
- Website
- www.axoltis.com/
- Email ID
- *****@axoltis.com
- Phone Number
- +33 **********
Sign up to download Axoltis Pharma's company profile
Axoltis Pharma's funding and investors
Axoltis Pharma has raised a total funding of $20.9M over 2 rounds. Its first funding round was on 2023. Its latest funding round was a Series A round on Dec 02, 2025 for $*****. 2 investors participated in its latest round. Axoltis Pharma has 4 institutional investors.
Here is the list of recent funding rounds of Axoltis Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 02, 2025 | 7482983 | Series A | 8419842 | 1971989 | 8231445 | 8940472 |
2023 | 3602 | PE | 6720 | 7264 | 9248 |
View details of Axoltis Pharma's funding rounds and investors
Axoltis Pharma's founders and board of directors
Founder? Claim ProfileAxoltis Pharma's employee count trend
Axoltis Pharma has 15 employees as of Aug 26. Here is Axoltis Pharma's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Axoltis Pharma's Investments and acquisitions
Axoltis Pharma has made no investments or acquisitions yet.
Reports related to Axoltis Pharma
Here is the latest report on Axoltis Pharma's sector:
News related to Axoltis Pharma
Media has covered Axoltis Pharma for a total of 3 events in the last 1 year, 2 of them have been about company updates.
•
Axoltis Pharma Reports Positive Phase 2 Data for NX210c in ALS StudyPharmaTimes•Sep 21, 2026•Axoltis Pharma
•
Axoltis Pharma's Phase II ALS Trial Fails Primary Endpoint, Company Pursues Exploratory Dataclinicaltrialsarena.com•Sep 16, 2026•Axoltis Pharma
•
Axoltis Pharma secures €18 million for ALS, Alzheimer’s and Parkinson’s research.EU-Startups•Dec 02, 2025•Axoltis Pharma, UI Investments, Kreaxi, First Momentum Ventures and 1 other
•
Axoltis Pharma presents promising results from phase 1b clinical trial of innovative drug candidate for neurodegenerative diseasesPipelinereview•Dec 12, 2023•Axoltis Pharma
•
InSilicoTrials and Axoltis to develop drugs for neurological disordersPharmaceutical Technology•Jul 28, 2023•InSilicoTrials, Axoltis Pharma
Are you a Founder ?
FAQs about Axoltis Pharma
Explore our recently published companies
- Bank of the West - East Orange based, 1973 founded, Unfunded company
- S. Middlesex FCU - Kentwood based, Unfunded company
- Muzeumluzyckie - Germany based, 2011 founded, Unfunded company
- SmartPod Technology - Bengaluru based, 2020 founded, Unfunded company
- Warbafdb - Uganda based, 2008 founded, Unfunded company
- Spksca - Schaumburg based, 1930 founded, Unfunded company
_1578994928313.png?format=webp&height=120&width=120)